Increased tumor-associated macrophages in the prostate cancer microenvironment predicted patients’ survival and responses to androgen deprivation therapies in Indonesian patients cohort

Yuri, Prahara; Shigemura, Katsumi; Kitagawa, Koichi; Hadibrata, Exsa; Risan, Muhammad; Zulfiqqar, Andy; Soeroharjo, Indrawarman; Hendri, Ahmad Zulfan; Danarto, Raden; Ishii, Aya; Yamasaki, Saya; Yan, Yongsheng; Heriyanto, Didik Setyo; Fujisawa, Masato

doi:10.1016/j.prnil.2019.12.001

Cited by 31 publications

(24 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abbreviations: AR, androgenic receptor; BPH, benign prostatic hyperplasia; IGF-1R, insulin-like growth factor-1 receptor; IQR, interquartile range; IR, insulin receptor; MVD, microvascular density; PCa, prostate cancer; PSA, prostate-specific antigen; PSMA, prostate specific membrane antigen; SRSF1, serine/arginine splicing factor 1.s This latter IHC finding is a is a quantitative measurement of angiogenesis. Although previous studies reported conflicting results as predictive value in PC,30,31 recently Yuri et al32 demonstrated that MVD number significantly influence response to systemic therapy in metastatic PC.Despite we could not speculate a potential a downstream role of SRSF-1 and PC aggressiveness in diabetic patients, we demonstrated that in this sub-cohort of patients, SRSF-1 positivity was related to greater cell (Ki-67 + ) and vascular…”

contrasting

confidence: 47%

SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)

et al. 2021

View full text Add to dashboard Cite

Objective: To study the association between insulin receptors (isoforms α and β), insulin growth factor-1 (IGF1) and serine/arginine splicing factor 1 (SRSF-1) in patients with prostate cancer (PC) and diabetes. Materials and Methods:We retrospectively analyzed data from 368 patients who underwent surgery for PC or benign prostatic hyperplasia (BPH) between 2010 and 2020 at the Department of Urology, University of Catania. Tissue microarray slides were constructed and they were stained for androgen receptor (AR), insulin receptor-α and -β, IGF1 (IGF1-R), Ki-67, and prostate specific membrane antigen (PSMA) expression using validated score. Results:The final cohort was represented by 100 patients with BPH and 268 with PC, with a median age of 68 years. We found that SRSF-1 expression was associated

show abstract

contrasting

confidence: 47%

SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Macrophages are phagocytic innate immune cells that regulate responses to tissue damage. Macrophages are promoted based on consecutive signals from the damaged microenvironment and mount proinflammatory responses to pathogens [ 29 ]. Macrophages are abundantly observed in growing cancer cells and mediate lymphocyte trapping according to interactions with CD8 T cells in tumor stroma.…”

Section: Tumor Microenvironment In Renal Cell Carcinomamentioning

confidence: 99%

Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review

Hah

Koo

2021

IJMS

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a malignant tumor associated with various tumor microenvironments (TMEs). The immune system is activated by the development of cancer and drives T cell anti-tumor response. CD8 T cells are known to improve clinical outcomes and sensitivity to immunotherapy, and play a crucial role against tumors. In contrast, tumor-associated macrophages (TAMs) suppress immunity against malignancy and lead to tumor progression. TAMs are promoted from damaged TMEs and mount proinflammatory responses to pathogens. Initial immunotherapy consists of interferon-α and interleukin-2. However, response to such therapy is unclear in most patients, and it is associated with high levels of toxicity. Immune checkpoint inhibitors (ICIs), which up-regulate immune responses by blocking the programed cell death protein 1 (PD-1) receptor, the ligand of PD-1, or cytotoxic T-lymphocyte-associated protein 4 T cells, have led to a new era of immunotherapy. Furthermore, combination strategies with ICIs have proven effective through several randomized controlled trials. We expect the next generation of immunotherapy to lead to better outcomes based on ongoing trials and inspire new therapeutic strategies.

show abstract

“…Numerous stimuli including chemokines can influence TAM polarisation from a proinflammatory (antitumour) M1 to an anti-inflammatory (protumour) M2 phenotype, which promotes tumour angiogenesis, tissue remodelling and tumour progression [ 32 ]. Interestingly, the frequency of TAMs has also been associated with clinical treatment response and disease progression [ 33 , 34 ]. In murine tumour models, low-dose gamma irradiation (LDI; 2 Gy) has been shown to promote repolarisation of M2-like TAMs towards M1-like inducible nitric oxide synthase (iNOS)-expressing TAMs, contributing to T-cell recruitment and tumour regression ( Figure 1 ) [ 35 ].…”

Section: Radiation Response In the Tumour Microenvironmentmentioning

confidence: 99%

Radiation Response in the Tumour Microenvironment: Predictive Biomarkers and Future Perspectives

Byrne

Tambe

Coulter

2021

JPM

View full text Add to dashboard Cite

Radiotherapy (RT) is a primary treatment modality for a number of cancers, offering potentially curative outcomes. Despite its success, tumour cells can become resistant to RT, leading to disease recurrence. Components of the tumour microenvironment (TME) likely play an integral role in managing RT success or failure including infiltrating immune cells, the tumour vasculature and stroma. Furthermore, genomic profiling of the TME could identify predictive biomarkers or gene signatures indicative of RT response. In this review, we will discuss proposed mechanisms of radioresistance within the TME, biomarkers that may predict RT outcomes, and future perspectives on radiation treatment in the era of personalised medicine.

show abstract

Increased tumor-associated macrophages in the prostate cancer microenvironment predicted patients’ survival and responses to androgen deprivation therapies in Indonesian patients cohort

Cited by 31 publications

References 30 publications

SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)

SRSF‐1 and microvessel density immunohistochemical analysis by semi‐automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study)

Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review

Radiation Response in the Tumour Microenvironment: Predictive Biomarkers and Future Perspectives

Contact Info

Product

Resources

About